,37,38,39,40 However, predictive information can be gained when stratifying patients with GC according to their molecular subtypes and the nature of their TP53 mutation,4,33,41,42,43 in particular when also including BCL2-associated X, neurexin 1, Yes-associated transcriptional regulator 1, and other oncogenic mutations.38 This evidence concerns the gene TP53 and gastric cancer.